Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Investigate the Efficacy and Safety of Nimotuzumab Combined With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Local Advanced Cervical Squamous Cell Carcinoma

NCT04678791 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04678791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04678791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Investigate the Efficacy and Safety of Nimotuzumab Combined With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Local Advanced Cervical Squamous Cell Carcinoma
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2020
Completion date
December 31, 2025
Enrollment
286 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical squamous cell carcinoma